BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22508824)

  • 1. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H; Okamoto I; Nakagawa K
    J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
    Costa DB; Kobayashi S
    J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
    [No Abstract]   [Full Text] [Related]  

  • 5. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
    Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
    [No Abstract]   [Full Text] [Related]  

  • 7. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 11. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
    Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y
    J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725
    [No Abstract]   [Full Text] [Related]  

  • 14. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
    Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
    [No Abstract]   [Full Text] [Related]  

  • 16. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.